首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 15 毫秒
1.
白细胞介素-4(interleukin-4,IL-4)是一种主要由2型T辅助细胞(Th2)分泌的多功能细胞因子,可特异性地与靶细胞表面的IL-4受体(interleukin-4 receptor,IL-4R)结合,发挥相应的生物学作用。在机体免疫反应中,IL-4/IL-4R可通过调节T细胞分化,抑制B淋巴细胞凋亡,诱发Ig E表型转换等方面引起哮喘、过敏等疾病。除此之外,IL-4/IL-4R还可以在肿瘤的发展中发挥不同的作用。因此,本文就IL-4/IL-4R对肿瘤发展影响的研究进展作一综述。  相似文献   

2.
目的:探讨IL-23/IL-17轴在脓毒症患者中的表达及意义.方法:符合诊断标准的脓毒症患者40例,以28天预后为终点,将患者分为存活组(n=21)和病死组(n=19),分析各组病人的急性生理和慢性健康评分(APACHE)Ⅱ和序贯器官衰竭估计(SOFA)评分,同时在入ICU第1天采取外周静脉血做IL-23和IL-17检测,并对病死率和IL-23、IL-17、APACHEⅡ、SOFA做相关性分析.结果:与存活组比较,病死组患者拥有较高的APACHEⅡ和SOFA评分(P<0.01),且外周血的IL-23和IL-17蛋白含量均明显升高(P<0.05).APACHEⅡ和SOFA评分、IL-17和IL-23含量与28天预后有明显的相关性(P<0.05).结论:脓毒症Th17细胞分泌的IL-23/IL-17增加,加重患者病情,在脓毒症发病机制中可能扮演重要角色.  相似文献   

3.
目的 观察培菲康治疗腹泻型肠易激综合征(IBS-D)的临床疗效并探讨其可能作用机制.方法 80例IBS-D患者随机分为2个试验组:培菲康联合匹维溴铵(A组)40例,匹维溴铵(商品名:得舒特)(B组)40例,并设健康对照组(C组)30例,疗程均为4周.采用双抗夹心ELISA法分别检测两组患者治疗前后和30名健康志愿者血清中IL-18/IL-10的含量.治疗结束后4周对治愈和显效患者进行随访.结果 (1)A组总有效率为88.89%,B组总有效率为65.62%,A组明显高于B组(P<0.05).远期疗效:停药4周后随访,A组有4例复发或加重,复发率为12.5%,B组有9例复发或加重,复发率为42.9%,两组间差异有统计学意义(P<0.01).(2)A组和B组治疗前IL-18水平明显高于C组,A组治疗后IL-18的水平与C组比较差异无统计学意义,而B组仍高于C组.两组患者治疗前IL-10水平明显低于C组,但在药物干预后A组IL-10的水平与C组比较差异无统计学意义,而B组仍低于C组.结论 培菲康能够有效治疗IBS-D,并能预防其复发,调节免疫可能是其主要治疗机制.  相似文献   

4.
炎症性肠病(Inflammatory bowel disease,IBD)的发病机制至今尚不明确,普遍认为是由肠黏膜免疫调节异常、持续性肠道感染、肠黏膜屏障缺损、遗传和环境等多种因素相互作用导致的。近年来,研究发现IBD患者血清中IL-21水平异常升高,提示IL-21/IL-21R信号可能在IBD的病变形成中发挥重要作用。IL-21是一种重要的具有多重生物学功能的细胞因子,通过对CD4+T细胞、CD8+T细胞、Th17细胞、B细胞、巨噬细胞、树突状细胞等多种细胞产生影响,从而参与IBD的发生发展。本文就IL-21/IL-21R信号在炎症性肠病发病机制中的研究进展进行综述。  相似文献   

5.
6.
目的:探讨鼻炎患者血清中白细胞介素-27(IL-27)、白细胞介素-17(IL-17)、白细胞介素-10(IL-10)在变应性中的表达以及临床意义。方法:选取2013年5月到2014年5月我院收治的变应性鼻炎患者60例为研究组,另外选取健康志愿者60例为对照组,应用酶联免疫吸附试验(ELISA)检测入选者血清中的IL-27、IL-17以及IL-10的表达情况,并分析其相关关系。结果:研究组血清中IL-27、IL-10水平显著低于对照组,差异具有统计学意义(P0.05);研究组IL-17水平显著高于对照组,差异具有统计学意义(P0.05);研究组患者血清中的IL-27和IL-17呈负相关关系(r=-0.372,P=0.035),IL-27和IL-10呈正相关关系(r=0.524,P=0.026),而IL-17和IL-10无相关关系(r=0.519,P=0.318)。结论:变应性鼻炎患者中IL-27和IL-10呈低表达,而IL-17呈高表达,IL-27可能对IL-17和IL-10具有免疫调节的作用。  相似文献   

7.

Background

Galectin-3 (gal-3), a member of the β-galactoside-binding animal lectins, is involved in the recruitment, activation and removal of neutrophils. Neutrophilic asthma is characterized by a persistent elevation of airway neutrophils and impaired efferocytosis. We hypothesized that sputum gal-3 would be reduced in neutrophilic asthma and the expression of gal-3 would be associated with other markers of neutrophilic inflammation.

Methods

Adults with asthma (n = 80) underwent a sputum induction following clinical assessment and blood collection. Sputum was dispersed for a differential cell count and ELISA assessment of gal-3, gal-3 binding protein (BP), interleukin (IL)-1β, IL-1 receptor antagonist (RA), IL-8 and IL-6. Gal-3 and gal-3BP immunoreactivity were assessed in mixed sputum cells.

Results

Sputum gal-3 (median, (q1,q3)) was significantly reduced in neutrophilic asthma (183 ng/mL (91,287)) compared with eosinophilic (293 ng/mL (188,471), p = 0.021) and paucigranulocytic asthma (399 ng/mL (213,514), p = 0.004). The gal-3/gal-3BP ratio and IL-1RA/IL-1β ratio were significantly reduced, while gal-3BP and IL-1β were significantly elevated in neutrophilic asthma compared with eosinophilic and paucigranulocytic asthma.

Conclusion

Patients with neutrophilic asthma have impairment in anti-inflammatory ratio of gal-3/gal-3BP and IL-1RA/IL-1β which provides a further framework for exploration into pathologic mechanisms of asthma phenotypes.

Electronic supplementary material

The online version of this article (doi:10.1186/s12931-014-0163-5) contains supplementary material, which is available to authorized users.  相似文献   

8.
Microglia are important innate immune effectors against invading CNS pathogens, such as Staphylococcus aureus (S. aureus), a common etiological agent of brain abscesses typified by widespread inflammation and necrosis. The NLRP3 inflammasome is a protein complex involved in IL-1β and IL-18 processing following exposure to both pathogen- and danger-associated molecular patterns. Although previous studies from our laboratory have established that IL-1β is a major cytokine product of S. aureus-activated microglia and is pivotal for eliciting protective anti-bacterial immunity during brain abscess development, the molecular machinery responsible for cytokine release remains to be determined. Therefore, the functional role of the NLRP3 inflammasome and its adaptor protein apoptosis-associated speck-like protein (ASC) in eliciting IL-1β and IL-18 release was examined in primary microglia. Interestingly, we found that IL-1β, but not IL-18 production, was significantly attenuated in both NLRP3 and ASC knockout microglia following exposure to live S. aureus. NLRP3 inflammasome activation was partially dependent on autocrine/paracrine ATP release and α- and γ-hemolysins produced by live bacteria. A cathepsin B inhibitor attenuated IL-β release from NLRP3 and ASC knockout microglia, demonstrating the existence of alternative inflammasome-independent mechanisms for IL-1β processing. In contrast, microglial IL-18 secretion occurred independently of cathepsin B and inflammasome action. Collectively, these results demonstrate that microglial IL-1β processing is regulated by multiple pathways and diverges from mechanisms utilized for IL-18 cleavage. Understanding the molecular events that regulate IL-1β production is important for modulating this potent proinflammatory cytokine during CNS disease.  相似文献   

9.
正肺动脉高压(pulmonary arterial hypertension,PAH)是一种发生在远端中小型肺动脉的疾病,主要与动脉肌化、内膜增厚和丛状损伤的形成有关。近年来,炎症和自身免疫也被认为是PAH病理过程中的重要因素。T细胞、B细胞、巨噬细胞等炎症细胞在进展型PAH的丛状损伤中有浸润。因此,这些细胞分泌的炎性因子可能与肺动脉内皮细胞(PAEC)和肺动脉平滑肌细  相似文献   

10.
目的:深入观察耐力训练对载脂蛋白E基因敲除(ApoE-/-)致动脉粥样硬化(AS)小鼠白介素18(IL-18)和白介素10(IL-10)的影响,探讨运动防治AS的可能机制。方法:选取8周龄雄性ApoE-/-小鼠20只:随机分为2组(n=10):AS模型组(AC组)和运动干预组(AE组),AE组进行跑台耐力训练;选取8周龄C57BL/6J雄性小鼠10只作为正常对照组(CC组)。实验持续12周,取主动脉制作冰冻切片,分别用于观察主动脉AS斑块和病理变化以及主动脉IL-18、IL-10蛋白表达;采用ELISA法检测血清IL-18、IL-10水平。结果:①12周高脂膳食致ApoE-/-小鼠发生典型的AS病变,耐力训练使AS斑块面积显著减少(P<0.01),病变程度显著减轻。②与CC组比较,AC组、AE组小鼠血清IL-18和IL-10水平均显著升高(P<0.01),且AC组IL-18/IL-10比值显著升高(P<0.01)。AE组血清IL-18水平及IL-18/IL-10比值均显著低于AC组(P<0.01)。③与CC组比较,AC组、AE组小鼠主动脉IL-10和IL-18蛋白表达均显著升高(P<0.01),AE组IL-10表达显著高于AC组(P<0.05),IL-18表达显著低于AC组(P<0.05)。结论:耐力训练通过降低血液和主动脉IL-18及提高IL-10水平,增强了主动脉血管抗炎能力,从而发挥抗AS的作用。  相似文献   

11.
The present review illustrates the current knowledge on the autocrine effect of IL-12, and the putative contribution of IL-23, on macrophages and dendritic cells, focusing on cell activation and microbicidal activity. Here, we present convincing evidence that IL-12 is not only a connective element between accessory cells and lymphocytes, but it is also a key molecule for programming the macrophage and dendritic cell functions.  相似文献   

12.
Interleukin (IL)-15 is essential for natural killer (NK), NKT and memory (m) CD8+ T cell development and function, and is currently under investigation as an immunotherapeutic agent for the treatment of cancer. Recently, the creation of IL-15 superagonist by complexing IL-15 and its high affinity receptor alpha (IL-15 Rα) in solution, inspired by the natural trans-presentation of IL-15, advances the potential of IL-15-based tumor immunotherapy. IL-15 superagonist shows promising advantages over monomeric IL-15 such as sustaining high circulating concentrations due to prolonged half-life and more potently stimulating NK and CD8+ T effector lymphocytes. So far, there are three different forms of recombinant IL-15 superagonist fusion protein based on configurational modifications. Gene therapy using engineered cells co-expressing IL-15/IL-15 Rα complex for cancer treatment is also emerging. All forms have demonstrated efficacy in causing tumor regression in animal studies, which provides strong rationale for advancing IL-15 superagonist through clinical trials. To date, there are fourteen phase I/II IL-15 superagonist trials in cancer patients and one phase I trial in HIV patients. Information generated by ongoing trials regarding the toxicity and efficacy of IL-15 superagonist is awaited. Finally, we elaborate on immunotoxicity caused by IL-15 superagonist in preclinical studies and discuss important safety considerations.  相似文献   

13.
摘要 目的:探讨血清白细胞介素-17(IL-17)、白细胞介素-32(IL-32)、白细胞介素-33(IL-33)、白细胞介素-37(IL-37)联合检测对接受硼替佐米为基础一线治疗方案的初治多发性骨髓瘤(MM)患者早期治疗反应性的预测价值。方法:选择2018年7月至2021年3月期间陕西省人民医院收治的初治MM患者176例为研究对象,所有患者均接受以硼替佐米为基础一线的治疗方案,根据早期治疗反应性分为敏感组(142例)和非敏感组(34例);采用酶联免疫吸附法检测并比较两组血清IL-17、IL-32、IL-33、IL-37水平,并分析其联合检测对早期治疗反应性的预测价值。结果:敏感组治疗前血清IL-17、IL-32水平低于非敏感组,IL-33、IL-37水平高于非敏感组(P<0.05)。多因素logistic回归分析显示,年龄≥65岁、血清IL-17≥29.70 pg/mL、IL-32≥63.02 ng/L、肿瘤分期III期是早期治疗反应性的危险因素(P<0.05),IL-33>141.97 pg/mL、IL-37>69.17 ng/L是保护因素(P<0.05)。血清IL-17、IL-32、IL-33、IL-37联合检测预测早期治疗反应性的曲线下面积(AUC)为0.866(95%CI:0.801~0.972)。结论:年龄、肿瘤分期、血清IL-17、IL-32、IL-33、IL-37是MM患者早期治疗反应性的影响因素,联合检测血清IL-17、IL-32、IL-33、IL-37水平对接受硼替佐米为基础一线治疗方案的初治MM患者早期治疗反应性预测价值较高。  相似文献   

14.
IL-18作为一种多效性细胞因子,在机体免疫应答及各种生理功能中发挥着重要的调节作用,根据猪IL-18基因序列设计1对引物,将编码猪IL-18的成熟蛋白基因亚克隆到杆状病毒转移载体pFastBacDual中,并在C端融合6个组氨酸标签以利于纯化,然后转化到含穿梭载体Bacmid的感受态细胞DH10Bac中,发生转座作用。将重组质粒转染昆虫细胞,SDS-PAGE可检测到分子量为18 kDa左右的重组蛋白,Western blotting证实该重组蛋白可与兔抗猪IL-18抗体发生特异性反应。纯化后蛋白能明显促进猪T淋巴细胞转化,表明所表达的IL-18具有较高的生物活性。此研究为进一步开发研制新型免疫佐剂奠定了基础。  相似文献   

15.
白细胞介素是由多种细胞产生并作用于多种细胞的一类细胞因子.白细胞介素家族成员包括白细胞介素-1(interleukin-1,IL-1)、白细胞介素-2(interleukin-2,IL-2)、白细胞介素-6(interleukin-6,IL-6)、多集落刺激因子、合成抑制因子等,影响细胞的增殖、生存、分化、迁移、侵袭、...  相似文献   

16.
摘要 目的:研究重症肺炎(SP)患者血清白细胞介素-18(IL-18)、白细胞介素-23(IL-23)、白细胞介素-33(IL-33)与肠道菌群和临床转归的关系。方法:选取2019年12月~2022年6月济南市人民医院收治的90例SP患者,记作研究组。另取同期收治的90例普通肺炎患者作为对照组。对比两组血清IL-18、IL-23、IL-33与肠道菌群含量,并以Pearson相关性分析两者的关系。此外,将研究组患者按照治疗后临床转归情况的差异分为好转组60例及恶化组30例,多因素Logistic回归分析SP患者临床转归的影响因素。结果:研究组血清IL-18、IL-23、IL-33水平高于对照组(均P<0.05)。研究组大肠埃希菌、肠球菌含量均高于对照组,而拟杆菌、双歧杆菌及乳酸杆菌含量均低于对照组(均P<0.05)。经Pearson相关性分析可得:血清IL-18、IL-23、IL-33与大肠埃希菌、肠球菌含量呈正相关关系,而与拟杆菌、双歧杆菌及乳酸杆菌含量呈负相关关系(均P<0.05)。好转组年龄及血清IL-18、IL-23、IL-33水平均低于恶化组,且机械通气与长期卧床人数占比均低于恶化组(均P<0.05)。经多因素Logistic回归分析发现:年龄大、机械通气、长期卧床以及血清IL-18、IL-23、IL-33水平高均是SP患者治疗后恶化的危险因素(均P<0.05)。结论:SP患者血清IL-18、IL-23、IL-33与肠道菌群密切相关,且随着上述三项血清指标水平的升高,患者临床转归越差。  相似文献   

17.
李激文  阮海林 《蛇志》2016,(4):488-490
正急性肺损伤(ALI)/急性呼吸窘迫综合征(ARDS)是由多种效应细胞、炎性介质共同参与,并呈现出级联放大的继发性弥漫性肺实质损伤和瀑布样炎症继发性损伤。据统计[1],ALI/ARDS的病死率在26%~35%,其致病环节众多、发病机制复杂、病因多元化,已成为临床危重病学研究的难点和热点问题。近年来,IL-6/GP130/STAT3信号通路靶向治疗急性肺损伤已成为了研究热点,为急性肺损伤患者提供了一种新的治疗方式,也为急性肺损伤患者带来新的希望。本文就IL-6/GP130/STAT3信号通路在急性肺损伤治  相似文献   

18.
19.
基因工程菌的发酵技术是基因工程药物大规模生产所必备的关键技术,本文对于重组GM-CDF/IL-3融合蛋白表达菌株E.coli BL21(DE3)(pFu)的生长及产物表达规律进行了探索,在此基础上进行高密度发酵研究,真体最终发酵密度达OD600值60以上,目的产物占菌体总蛋白25%以上。  相似文献   

20.
Hypertrophic scar (HS) is a severe fibrotic skin disease. It has always been a major problem in clinical treatment, mainly because its pathogenesis has not been well understood. The roles of bacterial contamination and prolonged wound inflammation were considered significant. IL-10 is a potent anti-inflammatory cytokine and plays a pivotal role in wound healing and scar formation. Here, we investigate whether IL-10 alleviates lipopolysaccharide (LPS)-induced inflammatory response and skin scarring and explore the possible mechanism of scar formation. Our results showed that the expression of TLR4 and pp65 was higher in HS and HS-derived fibroblasts (HSFs) than their counterpart normal skin (NS) and NS-derived fibroblasts (NSFs). LPS could up-regulate the expression of TLR4, pp65, Col I, Col III and α-SMA in NSFs, but IL-10 could down-regulate their expression in both HSFs and LPS-induced NSFs. Blocking IL-10 receptor (IL-10R) or the phosphorylation of STAT3, their expression was up-regulated. In addition, in vitro and in vivo models results showed that IL-10 could alleviate LPS-induced fibroblast-populated collagen lattice (FPCL) contraction and scar formation. Therefore, IL-10 alleviates LPS-induced skin scarring via IL-10R/STAT3 axis regulating TLR4/NF-κB pathway in dermal fibroblasts by reducing ECM proteins deposition and the conversion of fibroblasts to myofibroblasts. Our results indicate that IL-10 can alleviate the LPS-induced harmful effect on wound healing, reduce scar contracture, scar formation and skin fibrosis. Therefore, the down-regulation of inflammation may lead to a suitable scar outcome and be a better option for improving scar quality.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号